IGKV2OR22-4

Across TCGA pan-cancer cohorts, IGKV2OR22-4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGKV2OR22-4 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IGKV2OR22-4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGKV2OR22-4 expression acts as an unfavorable survival marker.

BLCA and LUSC are the cancer types where IGKV2OR22-4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.117	0.720	<.001	36	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	15	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IGKV2OR22-4–BLCA (OS)

Open the BLCA breakdown →